Check out our new  press release hub , powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop  here .
LOS ANGELES–(BUSINESS WIRE)–November 6, 2013–
Lion Biotechnologies, Inc. (OTC Markets: LBIO) has completed a       previously announced private financing with institutional and other       accredited investors for gross proceeds of $23.3 million. After paying       the placement agent fees and estimated offering expenses payable by the       Company, Lion Biotechnologies received net proceeds of approximately       $21.6 million.
At the closing, the Company issued 3,145,300 shares of common stock,       17,000 shares of its new Series A Convertible Preferred Stock, and       warrants to purchase a total of 11,645,300 shares of Common Stock.
Roth Capital Partners, LLC, served as the lead placement agent, with       Highline Research Advisors LLC a Division of Agincourt, LTD. acting       as the co-placement agent. Quogue Capital LLC was the lead investor,       with several additional institutions participating, including Perceptive       Advisors LLC, venBio Select Advisor, Three Arch Opportunity Fund, and       Broadfin Capital LLC.
“We are very pleased to have raised the capital we believe is required       to take our lead T-cell program into a Phase III clinical study for       metastatic melanoma as well as sponsor several additional combination       studies of check point inhibitors and T-cells,” said Manish Singh,       Ph.D., President and Chief Executive Officer of Lion Biotechnologies.       “The quality of the investors participating in this financing is a       strong endorsement of our clinical results to-date and of the potential       for tumor-infiltrating lymphocyte technology.”
The investors purchased units consisting of either (i) one share of       common stock and a warrant to purchase a share of common stock, or (ii)       one share of the newly authorized Series A Convertible Preferred Stock       and a warrant to purchase the number of shares of common stock initially       issuable upon the conversion of the preferred stock. The shares of       common stock (and accompanying warrants) were sold at $2.00 per share,       and the shares of Series A Convertible Preferred Stock (and accompanying       warrants) were sold at $1,000 per share. The shares of Series A       Convertible Preferred Stock have a stated value of $1,000 per share and       will initially be convertible into shares of common stock at a price of       $2.00 per share (subject to customary adjustment for stock splits,       reorganizations, and similar changes). Each warrant entitles the holder       the right to acquire one share of common stock at a price of $2.50 for a       period of five years.
The foregoing securities were offered in the private placement and have       not been registered under the Securities Act of 1933, as amended, or       applicable under state securities laws. Accordingly, the securities may       not be offered or sold in the United States except pursuant to an       effective registration statement or an applicable exemption from the       registration requirements of the Securities Act and such applicable       state securities laws. As part of the transaction, the Company has       agreed to file a resale registration statement on Form S-1 with the       Securities and Exchange Commission within 30 days of the closing for       purposes of registering the resale of (i) the shares of common stock       sold to the investors, and (ii) the common stock issuable upon the       conversion of the Series A Convertible Preferred Stock and the exercise       of the warrants issued in the private placement.
About Lion Biotechnologies
Lion Biotechnologies, Inc., formerly Genesis Biopharma, Inc., is engaged       in the development of T-cells and engineered T-cells for the treatment       of various cancers. The company’s lead product candidate is a       ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating       lymphocytes (TILs) for the treatment of patients with Stage IV       metastatic melanoma, and is based on a clinical CRADA with the National       Cancer Institute along with physician-sponsored investigational therapy       at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.genesis-biopharma.com/ .
Safe Harbor / Forward-Looking Statements
This press release contains “forward-looking statements” within the       meaning of the Private Securities Litigation Reform Act of 1995,       including statements regarding the use of funds raised in the private       placement and the potential of the Company’s technology to treat       metastatic tumors. These forward-looking statements are subject to risks       and uncertainties, including the company’s inability to file the       required registration statement, and the other risks detailed from time       to time in our filings with the Securities and Exchange Commission, and       represent our views only as of the date they are made and should not be       relied upon as representing our views as of any subsequent date. We do       not assume any obligation to update any forward-looking statements.
INVESTOR CONTACT:
